Literature DB >> 9696436

Occurrence and management of hepatitis B virus reactivation following kidney transplantation.

W Grotz1, J Rasenack, T Benzing, H Berthold, T Peters, E Walter, P Schollmeyer, L C Rump.   

Abstract

A 28-year-old woman was kidney transplanted. She had an inapparent hepatitis B virus (HBV) infection 2 years previously. At the time of transplantation she was hepatitis B surface antigen (HBsAg) negative, anti-HBs, anti-HBc, anti-HBe and anti-HCV antibody positive and her transaminase activities were within the normal range. The donor of the kidney allograft was HBV negative. Twelve weeks after transplantation a life-threatening liver failure occurred with a rapid rise of alanine aminotransferase (ALT) to 1427 U/l and a decrease of the prothrombin time to 25% of normal value. Anti-HBs had become negative, anti-HBc and anti-HBe titers had decreased. HBsAg became positive, associated with a HBV DNA of 3 x 10(8) genome equivalents/ml. Azathioprine and prednisone were withdrawn and foscarnet therapy was started. This therapy led to a decrease of ALT activity associated with an elimination of HBsAg and HBV DNA. Eight months after transplantation liver function tests were within the normal range. Graft rejection did not occur despite low or intermittent cessation of immunosuppressive therapy.

Entities:  

Mesh:

Year:  1998        PMID: 9696436

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  7 in total

Review 1.  Hepatic disorders in chronic kidney disease.

Authors:  Fabrizio Fabrizi; Piergiorgio Messa; Carlo Basile; Paul Martin
Journal:  Nat Rev Nephrol       Date:  2010-04-13       Impact factor: 28.314

2.  Hepatitis B virus reactivation in a patient with chronic GVHD after allogeneic peripheral blood stem cell transplantation.

Authors:  H Sakamaki; Y Sato; S I Mori; K Ohashi; S Tanikawa; H Akiyama; T Sasaki; K Hiruma
Journal:  Int J Hematol       Date:  2001-10       Impact factor: 2.490

3.  Fulminant hepatitis type B after chemotherapy in a serologically negative hepatitis B virus carrier with acute myelogenous leukemia.

Authors:  K Ishiga; T Kawatani; T Suou; F Tajima; H Omura; Y Idobe; H Kawasaki
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

4.  Hepatitis B reactivation after chemotherapy: two decades of clinical research.

Authors:  George K K Lau
Journal:  Hepatol Int       Date:  2008-03-05       Impact factor: 6.047

Review 5.  Hepatitis B virus infection and renal transplantation.

Authors:  Ming-Chao Tsai; Yen-Ta Chen; Yu-Shu Chien; Te-Chuan Chen; Tsung-Hui Hu
Journal:  World J Gastroenterol       Date:  2010-08-21       Impact factor: 5.742

6.  Prevalence of occult hepatitis B virus infection in haemodialysis patients from central Greece.

Authors:  Paraskevi Mina; Sarah P Georgiadou; Christos Rizos; George N Dalekos; Eirini I Rigopoulou
Journal:  World J Gastroenterol       Date:  2010-01-14       Impact factor: 5.742

Review 7.  Viral infection in renal transplant recipients.

Authors:  Jovana Cukuranovic; Sladjana Ugrenovic; Ivan Jovanovic; Milan Visnjic; Vladisav Stefanovic
Journal:  ScientificWorldJournal       Date:  2012-05-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.